These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 332534)
41. The history of drug regulations. Krzyzyk V Bull Parenter Drug Assoc; 1977; 31(3):156-60. PubMed ID: 328100 [No Abstract] [Full Text] [Related]
42. Pharmacy ...and the Food and Drug Law. Janssen WF Am Pharm; 1981 Apr; NS21(4):28-36. PubMed ID: 7013459 [No Abstract] [Full Text] [Related]
43. Unapproved generics. A generation of confusion. Stewart D Am Pharm; 1980 Nov; NS20(11):12-7. PubMed ID: 7006354 [No Abstract] [Full Text] [Related]
44. Fifty Years of Expert Advice - Pharmaceutical Regulation and the Legacy of the Drug Efficacy Study. Schwartz JL N Engl J Med; 2016 Nov; 375(21):2015-2017. PubMed ID: 27959733 [No Abstract] [Full Text] [Related]
45. Federal drug and narcotic legislation. Young JH Pharm Hist; 1995; 37(2):59-67. PubMed ID: 11639645 [No Abstract] [Full Text] [Related]
46. Jere Goyan, only pharmacist to lead FDA, dies at 76. Traynor K Am J Health Syst Pharm; 2007 Mar; 64(5):459. PubMed ID: 17322156 [No Abstract] [Full Text] [Related]
47. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked? Shulman SR; Brown JS Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017 [No Abstract] [Full Text] [Related]
48. Regulatory aspects of investigational new drugs. Arbit HM Am J Hosp Pharm; 1978 Jan; 35(1):81-5. PubMed ID: 341700 [TBL] [Abstract][Full Text] [Related]
49. A history of drug development in four acts. Kinch MS; Hoyer D Drug Discov Today; 2015 Oct; 20(10):1163-8. PubMed ID: 25908577 [No Abstract] [Full Text] [Related]
50. The cosmetic/drug dilemma: FDA regulation of alpha-hydroxy acids. Heymann LA Food Drug Law J; 1997; 52(4):357-75. PubMed ID: 10346670 [No Abstract] [Full Text] [Related]
51. The administration and development of federal statutes on foods and drugs in Canada. Pugsley LI Med Serv J Can; 1967 Mar; 23(3):387-449. PubMed ID: 4861831 [No Abstract] [Full Text] [Related]
52. The history and contemporary challenges of the US Food and Drug Administration. Borchers AT; Hagie F; Keen CL; Gershwin ME Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043 [TBL] [Abstract][Full Text] [Related]
53. The right to a trial: Should dying patients have access to experimental drugs? Groopman J New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539 [No Abstract] [Full Text] [Related]
54. Government regulations and the use of drugs. Hafkenschiel JH Calif Med; 1967 Aug; 107(2):159-63. PubMed ID: 4862066 [TBL] [Abstract][Full Text] [Related]
55. Revisiting "the origins of compulsory drug prescriptions". Marks HM Am J Public Health; 1995 Jan; 85(1):109-15. PubMed ID: 7832245 [TBL] [Abstract][Full Text] [Related]
56. Controversy over study of diabetes drugs continues for nearly a decade. Kolata GB Science; 1979 Mar; 203(4384):986-90. PubMed ID: 370980 [No Abstract] [Full Text] [Related]
58. Frances Oldham Kelsey. FDA medical reviewer leaves her mark on history. Bren L FDA Consum; 2001; 35(2):24-9. PubMed ID: 11444245 [No Abstract] [Full Text] [Related]
59. The making of policy through myth, fantasy and historical accident: the making of America's narcotics laws. Saper A Br J Addict Alcohol Other Drugs; 1974 Jun; 69(2):183-93. PubMed ID: 4614852 [No Abstract] [Full Text] [Related]
60. Scientific and legal viability of follow-on protein drugs. Dudzinski DM; Kesselheim AS N Engl J Med; 2008 Feb; 358(8):843-9. PubMed ID: 18287608 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]